How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,040 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Acetaminophen Given Per Os and Intravenous in Sinus Surgery

hypersensitivity to acetaminophen or to any excipients in the intravenous formulation chronic opioid use chronic pain alcohol or drug abuse Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03295214 Contacts Layout table for location contacts Contact: Amy (...) organization's list of essential medicines. The potential risks include liver damage, skin reactions and drug interactions when used with blood thinners at high doses. Acetaminophen has been extensively researched, in vitro and in vivo studies have found the drug to be safe when used at proper doses. Recently intravenous use of acetaminophen has gained popularity due to ease of use and ability to be given intraoperatively. This form of acetaminophen, although convenient, is around sixty two times the cost

2017 Clinical Trials

142. A Study to Evaluate Pharmacokinetics of Sonazoidâ„¢ Following Intravenous Bolus Injection in Healthy Volunteers

Last Update Posted : November 14, 2017 Sponsor: GE Healthcare Information provided by (Responsible Party): GE Healthcare Study Details Study Description Go to Brief Summary: The primary purpose of this study is to determine the Pharmacokinetics (PK) data of perfluorobutane (PFB) in blood and exhaled air following intravenous (I.V.) bolus injection of Sonazoid™ in healthy volunteers. Condition or disease Intervention/treatment Phase Healthy Drug: Sonazoid™ Phase 1 Study Design Go to Layout table (...) Intervention/treatment Experimental: Sonazoid™ 0.12 microliter (µl) Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 µl microbubbles (MB)/kilogram (kg) body weight. Drug: Sonazoid™ Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles. Other Name: perfluorobutane Experimental: Sonazoid™ 0.60 µl Participants will receive single I.V bolus injection of Sonazoid™ 0.60 µl MB/kg body weight. Drug: Sonazoid™ Single Dose

2017 Clinical Trials

143. Effect of Total Intravenous Anaesthesia With Propofol on Postoperative Pain After Bilateral Third Molar Surgery

Last Update Posted : March 12, 2019 Sponsor: The University of Hong Kong Information provided by (Responsible Party): Wong Sau Ching Stanley, The University of Hong Kong Study Details Study Description Go to Brief Summary: Propofol is one of the most commonly used intravenous anaesthetic drugs both for induction and maintenance of general anaesthesia. Some of the advantages of total intravenous anaesthesia (TIVA) with propofol include reduced nausea and vomiting, reduced atmospheric pollution (...) : December 23, 2016 Actual Primary Completion Date : March 30, 2018 Actual Study Completion Date : March 30, 2018 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Sham Comparator: Group S Patients will be anaesthetized by inhalational anaesthesia using sevoflurane. Drug: Sevoflurane Experimental: Group P Patients will be anaesthetized using total intravenous propofol. Drug: propofol Monitoring and other anaesthetic

2017 Clinical Trials

144. Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency

Phase Heart Failure, Systolic Iron Deficiency Drug: Ferric Carboxymaltose Other: blood withdrawal Phase 2 Detailed Description: Iron deficiency is highly prevalent in patients with HFREF and intravenous high-dose (HD) iron application has significantly improved clinically meaningful endpoints in such patients. The best evidence is existent for ferric carboxymaltose. Intravenous HD iron may influence phosphate metabolism via increases in levels of intact FGF23 and hence induce prolonged (...) Completion Date : October 25, 2017 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Patients with HFREF & CKD treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal Drug: Ferric Carboxymaltose single shot infusion Other Name: Ferinject Other: blood withdrawal for determination of serum and urinary biomarkers of chronic kidney

2017 Clinical Trials

145. Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery

Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03095404 Recruitment

2017 Clinical Trials

146. Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects

between all tested treatments. Condition or disease Intervention/treatment Phase Healthy Drug: BI 655130 Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 36 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Safety, Tolerability, and Pharmacokinetics of Two Dose Strengths of a Single Subcutaneous Dose of BI 655130 and One Single Intravenous Dose (...) of investigational drug Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day) Inability to refrain from smoking on specified trial days Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males) Drug abuse or positive drug screening Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial Intention to perform excessive physical activities within one week prior to administration of trial

2017 Clinical Trials

147. Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine (PubMed)

doses of naloxone 0.4 mg IV. He was started on a naloxone infusion at 0.2 mg/h and discharged 13 h after admittance awake, alert and oriented. The patient's urine sample screened negative for common drugs of abuse and total tricyclic antidepressants. A high performance liquid chromatography tandem mass spectrometry method was developed and validated to quantify tianeptine in urine. The calibration range was 1-100 ng/mL with linear regression correlation (r2) of 0.9996 or greater. The limit (...) Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine Tianeptine (7-[([3-chloro-6,11]-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl) amino] heptanoic acid S, S dioxide) is a tricyclic compound prescribed as an antidepressant in European countries, but is not currently approved for use in the United States. There are few published case reports of tianeptine intoxication. Presented is the first case of acute toxicity associated with the intravenous use of tianeptine

Full Text available with Trip Pro

2017 Journal of analytical toxicology

148. Intravenous Heroin Induces Rapid Brain Hypoxia and Hyperglycemia that Precede Brain Metabolic Response (PubMed)

Intravenous Heroin Induces Rapid Brain Hypoxia and Hyperglycemia that Precede Brain Metabolic Response Heroin use and overdose have increased in recent years as people transition from abusing prescription opiates to using the cheaper street drug. Despite a long history of research, many physiological effects of heroin and their underlying mechanisms remain unknown. Here, we used high-speed amperometry to examine the effects of intravenous heroin on oxygen and glucose levels in the nucleus (...) accumbens (NAc) in freely-moving rats. Heroin within the dose range of human drug use and rat self-administration (100-200 μg/kg) induced a rapid, strong, but transient drop in NAc oxygen that was followed by a slower and more prolonged rise in glucose. Using oxygen recordings in the subcutaneous space, a densely-vascularized site with no metabolic activity, we confirmed that heroin-induced brain hypoxia results from decreased blood oxygen, presumably due to drug-induced respiratory depression

Full Text available with Trip Pro

2017 eNeuro

149. Exploring the effect of intravenous lipid emulsion in acute methamphetamine toxicity (PubMed)

Exploring the effect of intravenous lipid emulsion in acute methamphetamine toxicity The increasing use of methamphetamine (METH) in the last decades has made it the second most abused drug. Advancs in the area of intravenous lipid emulsion (ILE) have led to its potential application in the treatment of poisoning. The present study aims to investigate the potential role of ILE as an antidote for acute METH poisoning.Two groups of six male rats were treated by METH (45 mg/kg), intraperitoneally (...) reduced freezing and stereotyped behaviors and increased rearing responses (P<0.05). Locomotor activity also returned to control levels especially during the last hours of the experiment. ILE administration decreased the prevalence of pulmonary emphysema in the lungs (P<0.05 and P<0.01) and percentages of TUNEL positive cells in the brain (P<0.05), in comparison with the control group.ILE could reduce the severity of METH- induced toxicity as well as mortality rate in the animals. Intravenous infusion

Full Text available with Trip Pro

2017 Iranian journal of basic medical sciences

150. Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses (PubMed)

Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses Food intake and use of drugs of abuse like cocaine share common central and peripheral physiological pathways. Appetitive hormones play a major role in regulating food intake; however, little is known about the effects of acute cocaine administration on the blood concentrations (...) of these hormones in cocaine users.We evaluated serum concentrations of six appetitive hormones: ghrelin (total and acyl-ghrelin), amylin, glucagon-like peptide-1 (GLP-1), insulin, leptin and peptide YY (PYY), as well as acute cardiorespiratory and subjective responses of 8 experienced cocaine users who received 25mg intravenous (IV) cocaine.Serum concentrations of GLP-1 (p=0.014) and PYY (p=0.036) were significantly decreased one hour following IV cocaine administration; there was a trend towards a decrease

Full Text available with Trip Pro

2017 Drug and alcohol dependence

151. Randomized Controlled Trial of Intravenous Acetaminophen for Post-Cesarean Delivery Pain Control. (PubMed)

Randomized Controlled Trial of Intravenous Acetaminophen for Post-Cesarean Delivery Pain Control. Cesarean delivery is a common surgery in the United States, with 1.3 million performed during 2009.1 Obstetricians must balance the growing concern with opioid abuse, dependence, and side effects with optimal postoperative pain control. Intravenous acetaminophen may represent an additional method to decrease the reliance on opioid medications and improve postoperative pain following cesarean (...) and postpartum care was standardized via study order sets. Study patients were given all medications in a standardized manner receiving either acetaminophen 1000 mg intravenously or 100 mL saline (placebo) every 8 hours for 48 hours for a total of 6 doses. The pharmacy prepared intravenous acetaminophen and saline in identical administration bags labeled study drug to ensure blinding. The initial dose of study drug was given within 60 minutes of skin incision. Quantity of breakthrough and scheduled analgesic

2017 American Journal of Obstetrics and Gynecology Controlled trial quality: predicted high

152. Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. (PubMed)

Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. 21610203 2012 07 27 2018 11 13 1552-4604 52 4 2012 Apr Journal of clinical pharmacology J Clin Pharmacol Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. 600-6 10.1177/0091270011401620 Lofwall M R MR University of Kentucky Department of Psychiatry, Lexington, KY 40509, USA. michelle.lofwall@uky.edu Moody D (...) Administration, Intranasal Adult Biological Availability Double-Blind Method Female Humans Injections, Intravenous Male Narcotics administration & dosage pharmacokinetics Opioid-Related Disorders epidemiology Oxycodone administration & dosage pharmacokinetics Tablets Young Adult 2011 5 26 6 0 2011 5 26 6 0 2012 7 28 6 0 ppublish 21610203 0091270011401620 10.1177/0091270011401620 PMC4006196 NIHMS570621 Eur J Pharm Sci. 1999 Dec;9(2):213-9 10620734 MMWR Morb Mortal Wkly Rep. 2009 Oct 30;58(42):1171-5 19875978

Full Text available with Trip Pro

2012 Journal of clinical pharmacology Controlled trial quality: uncertain

153. Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

the study will also be excluded History of excessive consumption of beverages containing caffeine (more than 4 cups or glasses per day). Patients who are not willing to abstain from the consumption of caffeine during certain periods of the study will also be excluded History or presence of alcohol or drug abuse within last 2 years History of smoking within last 2 years Poor metabolizers for CYP2C9, CYP2C19, or CYP2D6 based on genotyping Presence of any one or more of the following lab abnormalities (...) Caffeine Metoprolol Warfarin Omeprazole Antibodies, Monoclonal Adjuvants, Anesthesia Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs Anesthetics, Intravenous Anesthetics, General Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action

2016 Clinical Trials

154. An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates

study within 90 days of screening Recent or current history of alcohol or drug abuse Regular recent use of tobacco or nicotine products Positive serology for HBV, HCV, or HIV Pregnant or nursing Donation or loss of greater than 400 mL of blood within 3 months Serious adverse reaction or serious hypersensitivity to any drug Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using (...) An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2016 Clinical Trials

155. A Study to Evaluate the Drug-Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

), hepatitis B (surface antigen), or hepatitis C virus antibody at screening. Subject has a history of any drug allergy, hypersensitivity, or intolerance to acetaminophen or morphine/opioids or to any of the excipients in the IV or oral formulations used. Subject has an oxygen saturation of less than 95% while awake at screening and check-in. Subject has a positive test result for drugs of abuse (minimum: opioids, barbiturates, cannabinoids, benzodiazepines, cocaine, amphetamine) or alcohol (...) A Study to Evaluate the Drug-Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen A Study to Evaluate the Drug-Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2016 Clinical Trials

156. A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

units per week of alcohol for females and >21 units per week for males (one unit is defined as 8 g alcohol) within 3 months of the screening visit. History of drug or alcohol abuse according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-V) criteria within 1 year before screening or positive test result(s) for alcohol and/or drugs of abuse (such as barbiturates, opiates, cocaine, cannabinoids, amphetamines, and benzodiazepines) at screening or Day 1. History of tobacco (...) Drugs Anesthetics, Intravenous Anesthetics, General Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Arrhythmia Agents Cardiotonic Agents Enzyme Inhibitors Protective Agents Antiviral Agents Anti-Infective Agents

2016 Clinical Trials

157. Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Last Update Posted : January 15, 2019 Sponsor: Amplyx Pharmaceuticals Information provided by (Responsible Party): Amplyx Pharmaceuticals Study Details Study Description Go to Brief Summary: This is a Phase l double-blind, placebo-controlled, randomized study to investigate the safety, tolerability, pharmacokinetics, bioavailability and food effect of single doses of APX001 administered intravenously and orally, followed by an evaluation of the safety, tolerability, pharmacokinetics and drug-drug (...) the Drug-Drug Interaction Potential of APX001 Study Start Date : October 2016 Actual Primary Completion Date : April 20, 2017 Actual Study Completion Date : April 20, 2017 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Cohort 1a, Period A single intravenous dose, crossover Drug: APX001 single IV dose Drug: Matching placebo control Experimental: Cohort 1a, Period B single oral dose, crossover Drug: APX001

2016 Clinical Trials

158. This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

for drugs of abuse, alcohol or cotinine at Screening. Use of known inhibitors or inducers of CYP1A2, 2C9, 2C19, 2D6 or 3A4, including dietary supplements or herbal products containing St. John's wort (Hypericum perforatum) or other known CYP inducers or inhibitors within 30 days or 5 half-lives, whichever is greater prior to study CYP cocktail probe drug administration. Use of grapefruits, Seville oranges (sour or bitter oranges), starfruit and their juices, quinine, tonic water, dietary/herbal (...) Spondylarthritis Spondylitis Spinal Diseases Bone Diseases Musculoskeletal Diseases Arthritis Joint Diseases Midazolam Caffeine Metoprolol Warfarin Omeprazole Adjuvants, Anesthesia Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs Anesthetics, Intravenous Anesthetics, General Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents

2016 Clinical Trials

159. A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

by a physician. History or presence of drug or alcohol abuse. If female, pregnancy or breast-feeding. Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion. Any oral contraceptives during the screening period or for at least 15 days prior to the first dose of Period 1; any (...) Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs Anesthetics, Intravenous Anesthetics, General Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Arrhythmia Agents Antihypertensive Agents Sympatholytics Autonomic Agents Peripheral Nervous System Agents Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists

2016 Clinical Trials

160. Evidence based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity

Evidence based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity Journal of Psychopharmacology 0(0) 1 –54 © The Author(s) 2012 Reprints and permission: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881112444324 jop.sagepub.com Introduction The first British Association for Psychopharmacology evidence- based guidelines for ‘the pharmacological management of substance misuse, addiction and comorbidity’ were published in 2004 (...) , the word ‘patient’ is used through- out the document for consistency, although it is acknowledged that in many treatment centres, ‘client’ or ‘user’ is the preferred term. Scope of these guidelines Our aim is to provide helpful and pragmatic guidelines for clini- cians such as psychiatrists and GPs involved in prescribing to peo- ple with substance abuse or harmful use or addiction alone and with psychiatric comorbidity. However, the update should also be of interest to other practitioners

2012 British Association for Psychopharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>